PharmaResources (Shanghai) Co., Ltd. (SHE:301230)
China · Delayed Price · Currency is CNY 46.36
-0.89 (-1.88%)
Jan 21, 2026, 4:00 PM EST
SHE:301230 Revenue
PharmaResources (Shanghai) had revenue of 161.66M CNY in the quarter ending September 30, 2025, with 28.67% growth. This brings the company's revenue in the last twelve months to 667.47M, up 29.88% year-over-year. In the year 2024, PharmaResources (Shanghai) had annual revenue of 544.47M with 11.18% growth.
Revenue (ttm)
667.47M
Revenue Growth
+29.88%
P/S Ratio
9.54
Revenue / Employee
664.81K
Employees
1,085
Market Cap
6.37B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 544.47M | 54.75M | 11.18% |
| Dec 31, 2023 | 489.72M | 10.83M | 2.26% |
| Jan 1, 2023 | 478.88M | 30.67M | 6.84% |
| Jan 1, 2022 | 448.21M | 165.22M | 58.39% |
| Dec 31, 2020 | 282.99M | 37.79M | 15.41% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 1, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Novogene | 2.17B |
| Wuhan Hvsen Biotechnology | 1.67B |
| Kexing Biopharm | 1.52B |
| Xiangxue Pharmaceutical | 1.47B |
| Shenzhen Weiguang Biological Products | 1.14B |
| Beijing Konruns Pharmaceutical | 871.31M |
| R&G PharmaStudies | 789.45M |
| Lifecome Biochemistry | 587.04M |